Short Interest in Pfizer Decreases By 5.3% (PFE)
Shares of Pfizer (NYSE:PFE) were the target of a large decrease in short interest in the month of May. As of May 30th, there was short interest totalling 56,694,370 shares, a decrease of 5.3% from the May 15th total of 59,856,772 shares, Stock Ratings Network reports. Currently, 0.9% of the shares of the company are short sold. Based on an average trading volume of 26,841,182 shares, the short-interest ratio is currently 2.1 days.
In other Pfizer news, EVP Laurie J. Olson unloaded 36,275 shares of the stock on the open market in a transaction dated Thursday, June 12th. The stock was sold at an average price of $29.53, for a total value of $1,071,200.75. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
PFE has been the subject of a number of recent research reports. Analysts at JPMorgan Chase & Co. initiated coverage on shares of Pfizer in a research note on Wednesday, May 28th. They set an “overweight” rating and a $35.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Pfizer in a research note on Tuesday, May 27th. They now have a $31.00 price target on the stock. Finally, analysts at Goldman Sachs initiated coverage on shares of Pfizer in a research note on Tuesday, May 27th. They set a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and nine have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $32.83.
Shares of Pfizer (NYSE:PFE) opened at 29.45 on Tuesday. Pfizer has a 52 week low of $27.33 and a 52 week high of $32.96. The stock’s 50-day moving average is $29.45 and its 200-day moving average is $30.75. The company has a market cap of $187.9 billion and a P/E ratio of 9.24.
Pfizer (NYSE:PFE) last announced its earnings results on Monday, May 5th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.56 by $0.01. The company had revenue of $11.35 million for the quarter, compared to the consensus estimate of $12.07 billion. During the same quarter in the previous year, the company posted $0.54 earnings per share. The company’s revenue for the quarter was down 8.5% on a year-over-year basis. On average, analysts predict that Pfizer will post $2.24 earnings per share for the current fiscal year.
Pfizer Inc (NYSE:PFE) is a research-based, global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.